AGA Family of Websites: Gastro.org

AGA recommends shared decision-making approach for treatment of hepatocellular carcinoma (HCC)

The American Gastroenterological Association (AGA) issues new clinical practice guidelines on systemic therapy for HCC.

Bethesda, MD (Feb. 22, 2022) — Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, remains a deadly cancer with an incidence that has tripled in the United States since 1980. Individuals with HCC often present at an intermediate or advanced stage when decisions regarding systemic therapy are critical. Within the last few years, several new and novel FDA-approved treatments have become available, offering hope to patients with advances disease who are not candidates for curative treatments including surgeries. AGA has conducted a detailed review of all available literature to provide the most up-to-date clinical guidelines on the use of systemic therapy in the treatment of advanced HCC. These guidelines were published today in Gastroenterology, AGA’s official journal. 

The guideline was developed to not only guide hepatologists through care and treatment of their HCC patients, but also to highlight the importance of consulting a multidisciplinary team of health care professionals — including radiologists and oncologists — when developing a treatment plan. 

Top guideline recommendations 

  1. Systemic therapies are only recommended for patients with advanced HCC not amenable to surgical or radiological treatment but with preserved liver function. First line treatments include atezolizumab/bevacizumab, sorafenib, and lenvatinib with atezolizumab/bevacizumab showing modest improvement over sorafenib and thus considered first. 
  2. For second line treatment, recommendations were be made for cabozantinib, pembrolizumab, ramucirumab, and regorafenib recognizing that this is an area of great limitation with likely more data in future studies.
  3. Systemic therapy are not recommended for patients with poor liver function.
  4. Systemic therapy are not recommended as adjuvant therapy for HCC

Read the AGA Clinical Practice Guidelines on Systemic Therapy for Hepatocellular Carcinoma to review all 11 recommendations that detail specific patient scenarios and best treatment options.

Resources

Guidelines

Technical review

Spotlight

Clinical Decision Support Tool

# # #

Media contact: Courtney Reed, media@gastro.org, 301-272-0025

About the AGA Institute

The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. www.gastro.org.

AGA is now on Instagram.
Like AGA on Facebook.
Follow us on Twitter @AmerGastroAssn.
Check out our videos on YouTube.
Join AGA on LinkedIn.

About Gastroenterology

Gastroenterology is the most prominent journal in the field of gastrointestinal disease. As the official journal of the AGA InstituteGastroenterology delivers up-to-date and authoritative coverage of both basic and clinical gastroenterology. Regular features include articles by leading authorities and reports on the latest treatments for diseases. Original research is organized by clinical and basic-translational content, as well as by alimentary tract, liver, pancreas, and biliary content.

X